ClinicalTrials.gg
CompletedNCT05522231Updated Oct 20, 2026

Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)

A Phase 2/3 interventional study of fruquintinib+sintilimab and axitinib / everolimus in Advanced Renal Cell Carcinoma, sponsored by Hutchmed. Completed at 48 sites in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Hutchmed · Phase 2/3, Interventional, and Treatment

Updated Oct 20, 2026Now CompletedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
265
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 234 studies in Carcinoma, Renal Cell with a site in China — 111 open to participants now, 142 under way, 10 of them phase 3. Carcinoma, Renal Cell · China.

Enrollment
27th of 189
265 · median 66
Started
2022
with 21 others
Phase 2/3
Only one
of the 234
Registered
86th of 234
by date

Among the 234 studies in Carcinoma, Renal Cell with a site in China, this one is the 27th largest by enrollment of the 189 interventional ones that give a count, is one of 22 that started in 2022, is the only one in phase 2/3, and was the 86th registered.

Carcinoma, Renal Cell

2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 396 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

111 of the 234 studies in Carcinoma, Renal Cell with a site in China are open now. Recruiting first, the newest first:

106 more — sign in →

All 111 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 234 studies in Carcinoma, Renal Cell with a site in China, or all of them as a file.
02

Study summary

The study consists of two parts, the first part is a randomized, open-label, active-controlled study to evaluate the efficacy and safety of fruquintinib in combination with sintilimab versus axitinib or everolimus monotherapy as second-line treatment for locally advanced or metastatic renal cell carcinoma. The second part is a fruquintinib monotherapy factorial cohort study to evaluate the efficacy and safety of fruquintinib monotherapy as for second-line treatment of locally advanced or metastatic renal cell carcinoma.

Read the detailed description

The target populations for this study were patients with histologically or cytologically confirmed, locally advanced/ metastatic renal cell carcinoma who progressed during or after or intolerant to previous first-line VEGFR-TKI therapy.

A total of about 249-264 patients are planned to be enrolled in the study, among whom about 234 patients are planned to be enrolled in the first part. The patients who are successfully enrolled will be randomly assigned into the investigational arm or the control arm in a 1:1 ratio. The enrollment of part 2 will be started after that of part 1 is completed. About 15\~30 patients are planned to be enrolled in the second part. The patients who are successfully enrolled will receive fruquintinib monotherapy.

03

Conditions studied

  • Advanced Renal Cell Carcinoma
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 to 75 (inclusive) years of age on the date when ICF was signed;
  2. or cytologically confirmed renal clear cell carcinoma;
  3. Patients with locally advanced/ renal carcinoma;
  4. Patients with renal carcinoma who progressed during or after or intolerant to previous VEGFR-TKI therapy for advanced/metastatic disease;
  5. At least 1 according to 1.1;
  6. PS of 0 or 1;
  7. Adequate organ function.

Exclusion criteria

Exclusion Criteria:

  1. Had previously received therapy targeting immune modulatory receptors or related pathways (including but not limited to therapy targeting , CTLA-4, IDO, PD-L1, LAG-3, TIGIT, IL-2R and GITR, etc, but excluding related cytokine therapy such as IL2), excluding patients who had received immunotherapy such as anti-PD- (L) 1 antibody in /neoadjuvant therapy setting and did not progress within 6 months after discontinuation;
  2. Receiving approved systemic anti-tumor therapy within 2 weeks prior to the first dose;
  3. Toxicities caused by prior anti-tumor therapy before the first dose that did not recover to Grade 0 or 1 per the v5.0 or to the level specified in the enrollment criteria (excluding alopecia and peripheral neurotoxicity ≤ CTCAE Grade 2);
  4. medication within 4 weeks prior to randomization;
  5. Patients with active or inflammatory diseases;
  6. Known central nervous system (CNS) ;
  7. History of pneumonitis requiring therapy, or history of or current interstitial lung disease, or current active pulmonary infection, etc.;
  8. Toxicities caused by prior anti-tumor therapy before the first dose that did not recover to Grade 0 or 1 per the National Cancer Institute Common Terminology Criteria for Adverse events (NCI CTCAE) v5.0 or to the level specified in the enrollment criteria (excluding alopecia and peripheral neurotoxicities ≤CTCAE Grade 2 caused by platinum-based chemotherapy; thyroid dysfunction with stable disease control after symptomatic treatment);
  9. (HIV) Infection (HIV 1/2 Antibody positive);
  10. Uncontrolled hypertension despite standard therapy;
  11. Patient with evidence or history of haemorrhagic tendency within 2 months prior to the first dose, regardless of severity.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
265 participants (actual)

Study arms

  • Experimental
    Investigational arm

    fruquintinib, 5 mg, QD, PO, 2 weeks on/1 week off, 3 weeks/cycle; sintilimab, 200 mg, IV infusion, Q3W, 3 weeks/cycle.

    Drug: fruquintinib+sintilimab

  • Active comparator
    Control arm (comparator)

    axitinib, 5 mg, twice daily (BID), PO, 3 weeks/cycle, dose escalation will be at the investigator 's discretion ;Everolimus, 10 mg, QD, PO, 3 weeks/cycle.

    Drug: axitinib / everolimus

  • Other
    Fruquintinib monotherapy factorial study

    fruquintinib, 5 mg, QD, PO, 3 weeks on/ 1 week off, 4 weeks/cycle.

    Drug: fruquintinib

Interventions

  • Drugfruquintinib+sintilimab

    Drug pages: HMPL-013 · Sintilimab

    fruquintinib, 5 mg, QD, PO, 2 weeks on/1 week off, 3 weeks/cycle; sintilimab, 200 mg, IV infusion, Q3W, 3 weeks/cycle.

    Also known as: HMPL-013 + IBI308

  • Drugaxitinib / everolimus

    Drug pages: Axitinib · Everolimus

    axitinib, 5 mg, twice daily (BID), PO, 3 weeks/cycle, dose escalation will be at the investigator 's discretion based on clinical; everolimus, 10 mg, QD, PO, 3 weeks/cycle.

  • fruquintinib, 5 mg, QD, PO, 3 weeks on/ 1 week off, 4 weeks/cycle.

    Also known as: HMPL-013

06

What researchers measure

Primary outcomes

  1. Progression free survival (PFS) in Part I

    PFS per RECIST 1.1 by BIRC

    Time frame: Time from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 20 months.

  2. Objective response rate (ORR) in Part II

    ORR per RECIST 1.1 by investigator

    Time frame: Time from the date of first treatment administration until disease progression or the introduction of a new treatment, assessed up to 20 months.

Secondary outcomes

  1. PFS

    PFS per RECIST 1.1

    Time frame: Time from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 20 months.

  2. Safety in Part I

    Severity and Incidence of Adverse event (AEs) and findings in Laboratory test, vital signs, 12-lead Electrocardiogram (ECG), etc. in Part I

    Time frame: Through study completion, assessed up to 20 months.

  3. Quality of life in Part I

    Quality of life questionnaire analysis in Part I, the questionnaire include European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). It consists of 30 questions, divided into 15 categories, including 5 functional categories (physical, role, emotional, cognitive, and social), 3 symptom categories (fatigue, pain, nausea and vomiting), 1 overall health status/life quality category, and 6 individual items (each item represents a symptom). For questions 1 to 28, the scores of 1 to 4 correspond to the levels of "none", "a little", "quite", and "very", while for questions 29 and 30, the scores of 1 to 7 correspond to the range from "very bad" to "very good". The scoring rules state that higher scores in the functional categories and overall health status category indicate better functional conditions and life quality, while higher scores in the symptom categories indicate more symptoms or problems (and poorer life quality).

    Time frame: Through study completion, assessed up to 20 months.

  4. Quality of life in Part I

    Quality of life questionnaire analysis in Part I, the questionnaire include Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI-15). It was developed based on 34 symptoms related to kidney cancer, consisting of 15 questions, covering four aspects: symptom signs, respiratory symptoms, quality of life, and emotional symptoms. Each question has a score ranging from 0 to 4, corresponding to "not at all", "a little", "somewhat", "quite", and "very". The higher the score, the milder the symptoms (and the better the quality of life). The total score of the 15 individual questions ranges from 0 to 60.

    Time frame: Through study completion, assessed up to 20 months.

  5. Safety in Part II

    Severity and incidence of AEs and findings in such as Laboratory test, vital signs, 12-lead ECG, etc. in Part II.

    Time frame: Through study completion, assessed up to 20 months.

  6. Disease control rate (DCR)

    PFS per RECIST 1.1

    Time frame: Time from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 20 months.

  7. ORR

    ORR per RECIST 1.1

    Time frame: Time from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 20 months.

  8. Duration of response (DoR)

    DoR per RECIST 1.1

    Time frame: Time from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 20 months.

  9. Time to Response (TTR)

    TTR per RECIST 1.1

    Time frame: Time from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 20 months.

  10. OS

    OS

    Time frame: Time from date of randomization until the date of death from any cause, assessed up to 20 months.

07

Study locations

48 sites
  • Beijing Chao-Yang Hospital, Capital Medical University
    Beijing, China
  • Cancer Hospital Chinese Academy of Medical Sciences
    Beijing, China
  • Peking Union Medical College Hospital
    Beijing, China
  • Peking University First Hospital
    Beijing, China
  • Peking University Third Hospital
    Beijing, China
  • The First Affiliated Hospital of Bengbu Medical College
    Bengbu, China
  • The First Hospital of Jilin University
    Changchun, China
  • Hunan Cancer Hospital
    Changsha, China
  • Xiangya Hospital Central South University
    Changsha, China
  • Sichuan Provincial People's Hospital
    Chengdu, China
  • West China Hospital of Sichuan University
    Chengdu, China
  • Chongqing University Cancer Hospital
    Chongqing, China
  • The First Affilated Hospital of Fujian Medical University
    Fuzhou, China
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Guangzhou, China
  • Sun Yat-sen University Cancer Center
    Guangzhou, China
  • The First Affiliated Hospital, Sun Yat-sen University
    Guangzhou, China
  • The First Affiliated Hospital, Zhejiang University
    Hangzhou, China
  • Harbin Medical University Cancer Hospital
    Ha’erbin, China
  • Anhui Provincial Hospital
    Hefei, China
  • The First Affiliated Hospital of Anhui Medical University
    Hefei, China
  • Qilu Hospital of Shandong University
    Jinan, China
  • Shandong Cancer Hospital & Institute
    Jinan, China
  • Yunnan Cancer Hospital
    Kunming, China
  • Lanzhou University Second Hospital
    Lanzhou, China
  • The First Affiliated Hospital of Nanchang University
    Nanchang, China
  • Jiangsu Cancer Hospital
    Nanjing, China
  • Jiangsu Province Hospital
    Nanjing, China
  • Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School
    Nanjing, China
  • Guangxi Medical University Cancer Hospital
    Nanning, China
  • Nantong Tumor Hospital
    Nantong, China
  • The Affiliated Hospital of Qingdao University
    Qingdao, China
  • Fudan University Shanghai Cancer Center
    Shanghai, China
  • Renji Hospital,Shanghai Jiaotong University School of Medicine
    Shanghai, China
  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine
    Shanghai, China
  • Shanghai General Hospital
    Shanghai, China
  • Zhongshan Hospital Fudan University
    Shanghai, China
  • Liaoning Cancer Hospital & Institution
    Shenyang, China
  • The First Hospital of China Medical University
    Shenyang, China
  • The Second Hospital of Tianjin Medical University
    Tianjin, China
  • Tianjin Medical University Cancer Institute & Hospital
    Tianjin, China
  • The First Affiliated Hospital of Wenzhou medical university
    Wenzhou, China
  • Tongji Hospital Tongji Medical College of HUST
    Wuhan, China
  • Wuhan Union Hospital of China
    Wuhan, China
  • The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hosiptal)
    Xi'an, China
  • The First Affiliated Hospital of Xiamen University
    Xiamen, China
  • Henan Cancer Hospital
    Zhengzhou, China
  • Henan Provincial People's Hospital
    Zhengzhou, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Oct 2022 to primary completion in Aug 2026, 46 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Jan 2025 → Aug 2026 and completion Mar 2025 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2022
First posted
Aug 30, 2022
StartActual
Oct 27, 2022
Primary completionActual
Aug 28, 2026was Jan 2025
CompletionActual
Aug 28, 2026was Mar 2025
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 20, 2026
Sites
1 site added, 1 site removed
Show site
  • Harbin Medical University Cancer Hospital · Ha’erbin, China
Show 1 removed
  • Harbin Medical University Cancer Hospital · Ha'erbin, China
Oct 20, 2026
Primary completion
Jan 2025→Aug 28, 2026 (actual)
Oct 20, 2026
Study completion
Mar 2025→Aug 28, 2026 (actual)
Oct 20, 2026
Secondary outcomes
1 added, 1 description edited
What changed in the outcomes
  • AddedQuality of life in Part ITime frame: Through study completion, assessed up to 20 months.
  • DescriptionQuality of life in Part I: how it is measured was reworded
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Active, not recruiting→Completed
    1 site added, 1 site removed
    Show site
    • Harbin Medical University Cancer Hospital · Ha’erbin, China
    Show 1 removed
    • Harbin Medical University Cancer Hospital · Ha'erbin, China
    Primary completion Jan 2025→Aug 28, 2026 (now actual)
    Study completion Mar 2025→Aug 28, 2026 (now actual)
    Secondary outcomes 1 added, 1 description edited
    What changed in the outcomes
    • AddedQuality of life in Part ITime frame: Through study completion, assessed up to 20 months.
    • DescriptionQuality of life in Part I: how it is measured was reworded
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05522231
Lead sponsor
Hutchmed
Responsible party
Sponsor
First posted
Aug 30, 2022
Start date
Oct 27, 2022
Primary completion
Aug 28, 2026
Completion
Aug 28, 2026
Last update
Oct 20, 2026

Study contacts

Dingwei Ye
principal investigator · Fudan University
Zhi Song He
principal investigator · Peking University First Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: HMPL-013 · Sintilimab

Start the discussion